Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2001-11-06
2004-05-18
Ramsuer, Robert W. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
C514S472000, C549S491000, C549S472000
Reexamination Certificate
active
06737440
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the treatment of microbial infections caused by
Mycobacterium tuberculosis,
Trypanosoma spp.,
Candida albicans,
Aspergillus spp.,
Cryptosporidium parvum, Giardia lamblia,
Plasmodium spp.,
Pneumocystis carinii, Toxoplasma gondii, Fusarium solani,
and
Cryptococcus neoformans.
BACKGROUND OF THE INVENTION
The incidence of microbial infections (e.g., mycobacterial, fungal and protozoal infections) in the immunocompromised population has significantly increased over the past several years. In particular, Candida species, especially
Candida albicans,
are often significant pathogens in patients infected with human immunodeficiency virus (HIV). Another pathogen,
Pneumocystis carinii,
causes a form of pneumonia (PCP) that is believed to be one of the leading causes of death in patients suffering from AIDS.
Human African trypanosomiasis (HAT) has reemerged as a threat to over 60 million people. Current estimates are that between 350,000 and 450,000 people are infected.
Other severe and life-threatening microbial infections are caused by
Mycobacterium tuberculosis,
Aspergillus spp.,
Cryptosporidium parvum, Giardia lamblia,
Plasmodium spp.,
Toxoplasma gondii, Fusarium solani,
and
Cryptococcus neoformans.
The antimicrobial properties of dicationic molecules have been studied since the 1930's. Compounds of this type have typically utilized amidine groups as the cationic moieties, and their activities against a number of pathogens including
Cryptosporidium parvum, Giardia lamblia,
Leishmania spp., Plasmodium spp.,
Pneumocystis carinii, Toxoplasma gondii,
Trypanosoma spp.,
Candida albicans,
Aspergillus spp., and
Cryptococcus neoformans
have been reported. See e.g., King, H. et al.,
Ann. Trop. Med. Parasitol.
1938, 32,177-192; Blagburn, B. L. et al.,
Antimicrob. Agents Chemother.
1991, 35, 1520-1523; Bell, C. A. et al.,
Antimicrob. Agents Chemother.
1991, 35, 1099-1107; Bell, et al.,
Antimicrob. Agents Chemother.
1990, 34, 1381-1386; Kirk, R. et al.,
Ann. Trop. Med. Parastiol.
1940, 34, 181-197; Fulton, J. D.
Ann. Trop. Med. Parasitol.
1940, 34, 53-66; Ivady, V. G. et al.,
Monatschr. Kinderheilkd.
1958, 106, 10-14; Boykin, D. W. et al.,
J. Med. Chem.
1995, 38, 912-916; Boykin, D. W. et al.,
J. Med. Chem.
1998, 41, 124-129; Francesconi et al.,
J. Med. Chem.
1999, 42, 2260-2265; Lindsay, D. S. et al.,
Antimicrob. Agents Chemother.
1991, 35, 1914-1916; Lourie, E. M; et al.,
Ann. Trop. Med. Parasitol.
1939, 33, 289-304; Lourie, E. M. et al.,
Ann. Trop. Med. Parasitol.
1939, 33, 305-312; Das, B. P. et al.,
J Med. Chem.
1976, 20, 531-536; Del Poeta, M. et al.,
J. Antimicrob. Chemother.
1999, 44, 223-228; Del Poeta, M. et al.,
Antimicrob. Agents Chemother.
1998, 42, 2495-2502; Del Poeta, M. et al.,
Antimicrob. Agents Chemother.
1998, 42, 2503-2510.
Despite the broad range of activity exhibited by diamidines, only one compound of this chemical type, pentamidine, has seen significant clinical use. Pentamidine has been used clinically against African trypanosomiasis, antimony-resistant leishmaniasis and
P. carinii
pneumonia. See e.g., Apted, F. I. C.,
Pharmacol. Ther.
1980, 11, 391-413; Bryceson, A. D. M. et al.,
Trans. Roy. Soc. Trop. Med. Hyg.
1985, 79, 705-714; Hughes, W. T.; et al.,
Antimicrob. Agents Chemother.
1974, 5, 289-293.
A number of compounds in this class of dicationic molecules have been shown to bind to the minor-groove of DNA at AT-rich sites and the details of their interaction with the minor-groove have been elucidated from biophysical studies and from several crystal structures. It is hypothesized that these types of molecules exert their biological activity by first binding to DNA and then by inhibiting one or more of several DNA dependent enzymes (i.e., topoisomerases, nucleases, etc.) or possibly by direct inhibition of transcription. See, Tanious, F. A. et al.,
J. Biomol. Struct.
&
Dyn.
1994, 11, 1063-1083.; Wilson, W. D. et al.,
J. Am. Chem. Soc.
1998, 120, 10310-10321; Bailly, C. et al.,
Anti
-
Cancer Drug Design,
1999, 14, 47-60; Mazur, et al.,
J. Molecular Biology
2000, 300, 321-337; Trent, J. O.; et al.,
J. Med. Chem.
1996, 36, 4554-4562; Guerri, A. et al.,
Nucleic Acids Res.
1998, 26, 2873-2878; Laughton, C. A. et al.,
Biochemistry
1996, 35, 5655-5661; Beerman, T. A. et al.,
Biochim. Biophys. Acta
1992, 1131, 52-61; Bell, C. A.; et al.,
Antimicrob. Agents Chemother.
1993, 37, 2668-2673; Dykstra, C. C. et al.,
Antimicrob. Agents Chemother.
1994, 38, 1890-1898; Hildebrandt, E. et al.,
J. Euk. Microbial.
1998, 45, 112-121; Henderson, D. et al.,
Nature Medicine
1995, 1, 525-527; Fitzgerald, D. J.; et al.,
J. Biol. Chem
1999, 274, 27128-27138.
2,5-Diphenylfuran and 2,4-diphenylfuran diamidines have been found to be highly effective treatments in animal models for
Pneumocystis carinii
and
Cryptosporidium parvum.
See Blagburn, B. L. et al.,
Antimicrob. Agents Chemother.
1991, 35, 1520-1523; Boykin, D. W. et al.,
J. Med. Chem.
1995, 38, 912-916; Boykin, D. W. et al.,
J. Med. Chem.
1998, 41, 124-129; Francesconi, I. et al.,
J. Med. Chem.
1999, 42, 2260-2265; Tidwell, R. R.
J. Parasitol.
1998, 84, 851-856. Furthermore, these molecules have shown antifungal activity in vitro against
Candida albicans
and
Cryptococcus neoformans.
See, Del Poeta, M. et al.,
J. Antimicrob. Chemother.
1999, 44, 223-228; Del Poeta, M. et al.,
Antimicrob. Agents Chemother.
1998, 42, 2495-2502; Del Poeta, M. et al.,
Antimicrob. Agents Chemother.
1998, 42, 2503-2510.
Although there are reports of antimicrobial activity of guanidino compounds, this class of cationic compounds has not been studied as extensively as their amidino analogs. See Lourie et al.,
Ann. Trop. Med. Parasitol.
1937, 31, 435-445.
SUMMARY OF THE INVENTION
The synthesis, DNA-binding affinities and antimicrobial properties of 2,5-bis{[alkyl(or aryl)imino]aminophenyl}furans and thiophenes are described. These compounds have the imino group of the amidine attached to an “anilino” nitrogen (in contrast to the known amidino furans in which the imino group is directly attached to the aryl ring). These compounds, hereafter, are referred to as “reversed” amidines. The various effects of placing substituents on the central phenyl rings of the 2,5-diphenylfuran framework of this class of compounds are also described.
One aspect of the invention relates to novel compounds that are useful in treating microbial infections caused by
Mycobacterium tuberculosis,
Trypanosoma spp.,
Candida albicans,
Aspergillus spp.,
Cryptosporidium parvum, Giardia lamblia,
Plasmodium spp.,
Pneumocystis carinii, Toxoplasma gondii, Fusarium solani,
and
Cryptococcus neoformans.
Compounds of the present invention have a structure according to Formula I:
wherein:
R
1
, R
2
, R
3
and R
4
are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;
R
5
is H, alkyl or aryl;
R
6
is H, alkyl, aryl, or NR
7
R
8
, wherein R
7
and R
8
are each independently selected from the group consisting of H, alkyl and aryl; and
X is O, S or NR
9
, wherein R
9
is H or alkyl.
Additional aspects of the invention include pharmaceutical compositions comprising a compound having a structure according to Formula I, or a pharmaceutical salt thereof (i.e., an “active compound”), in a pharmaceutically acceptable carrier. Pharmaceutical compositions of the present invention are useful in the treatment of microbial infections caused by
Mycobacterium tuberculosis,
Trypanosoma spp.,
Candida albicans,
Aspergillus spp.,
Cryptosporidium parvum, Giardia lamblia,
Plasmodium spp.,
Pneumocystis carinii, Toxoplasma gondii, Fusarium solani,
and
Cryptococcus neoformans.
Certain aspects of the invention relate to methods of treating microbial infections caused by
Mycobacterium tuberculosis,
Trypanosoma spp.,
Candida albicans,
Aspergillus spp.,
Cryptosporidium parvum, Giardia lamblia,
Plasmodium spp.,
Pneumocystis carinii, Toxoplasma gondii, Fus
Boykin David W.
Perfect John R.
Stephens Chad F.
Tidwell Richard R.
Wilson W. David
Jenkins & Wilson & Taylor, P.A.
Ramsuer Robert W.
Sackey Ebenezer
The University of North Carolina at Chapel Hill
LandOfFree
Synthesis and antimicrobial activity of novel dicationic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis and antimicrobial activity of novel dicationic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis and antimicrobial activity of novel dicationic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3266432